Not medical advice. Talk to your provider before using any peptide. Full disclaimer
Tesamorelin
Beginner tier: 1.4 mg, daily · FDA label
Also known as: Egrifta, Egrifta SV, Egrifta WR
Visceral fat fell 14 to 18% in 26 weeks across two Phase 3 trials that randomized 816 patients (EGRIFTA SV label, section 14). The tesamorelin peptide (Egrifta) is an FDA-approved GHRH analog that triggers pulsatile GH release, targeting visceral adipose tissue. Subcutaneous bioavailability sits below 4%, yet receptor-level potency still produces reliable IGF-1 elevation and consistent abdominal fat loss. The gains need ongoing use; visceral fat came back within six months of stopping in both trials. About half of trial patients formed anti-tesamorelin antibodies, but visceral fat and IGF-1 changes were similar with or without them (section 12.6). Adults with stubborn visceral belly fat, HIV lipodystrophy patients, and those pursuing GH optimization through the most potent available GHRH analog are the primary users.
What Is Tesamorelin?
Eighteen percent less visceral fat at six months. That's the headline number from the first of two double-blind, placebo-controlled Phase 3 trials, which together randomized 816 participants. The second trial landed at 14% (EGRIFTA SV label, section 14). The tesamorelin peptide (trade name Egrifta SV, also marketed as Egrifta WR, compound code TH9507 (CAS 218949-48-5)) is a synthetic 44-amino-acid GHRH analog with an added trans-3-hexenoic acid modification that extends stability beyond native GHRH.
The mechanism is straightforward. Tesamorelin binds the GHRH receptor on anterior pituitary somatotrophs, producing pulsatile GH release rather than flat tonic elevation. That GH pulse drives hepatic IGF-1 production, and IGF-1 mediates the downstream lipolysis, targeting visceral adipose depots. Subcutaneous bioavailability runs below 4% per the FDA label (Section 12.3), yet the receptor-level response is potent enough to produce measurable body composition changes.
In clinical practice, the FDA approved tesamorelin in 2010 for HIV-associated lipodystrophy with excess visceral adipose tissue. Falutz and colleagues published the second trial on its own in 2010 (n=404)[1]. Visceral fat fell 10.9% (21 cm squared) at six months, versus a 0.6% drop on placebo. Patients who stayed on tesamorelin reached about 18% at 12 months. A pooled analysis of both trials (806 patients)[6] put the 26-week treatment effect at 15.4%. Beyond HIV, the off-label use has expanded considerably. Stanley and colleagues published a 2019 Lancet HIV trial [2] showing 35% of patients achieved liver fat below 5% at 12 months, establishing a potential NAFLD benefit. Baker et al. [3] demonstrated improved executive function in older adults and MCI patients after 20 weeks of GHRH treatment in a 152-person RCT. Community dosing follows the 2 mg daily Phase 3 trial dose, injected subcutaneously into the abdomen, with most protocols running 12 to 26 weeks followed by a rest period. The current EGRIFTA SV label dose is 1.4 mg daily.
Sermorelin was discontinued by EMD Serono in 2008, and FDA withdrew its approval in 2009, not for safety or effectiveness reasons. That leaves tesamorelin with the only active FDA approval among GHRH analogs. Both clear fast, with label half-lives of 8 to 11 minutes for tesamorelin and 11 to 12 minutes for sermorelin.
How Tesamorelin Works
Tesamorelin binds the growth hormone releasing hormone receptor (GHRH-R) on anterior pituitary somatotroph cells. Tesamorelin is a modified analog of endogenous GHRH(1-44)NH2 with a trans-3-hexenoic acid group attached to the tyrosine at position 1. That chemical modification protects against enzymatic degradation, but clearance is still fast. The current EGRIFTA labels (section 12.3) list a mean half-life of 8 minutes for SV and 11 minutes for WR after one subcutaneous dose.
Once GHRH-R activates, the intracellular signaling cascade mirrors what happens with natural GHRH. Cyclic AMP rises in somatotrophs, calcium channels open, and GH vesicles release into the bloodstream. The resulting GH pulse peaks quickly; Tmax occurs at approximately 9 minutes post-injection. GH then stimulates hepatic IGF-1 synthesis. IGF-1 is the workhorse molecule for tissue-level effects: lipolysis in visceral adipose, protein synthesis in muscle, collagen turnover, and hepatic fat metabolism.
The visceral fat selectivity is a GH-pathway feature, not a tesamorelin-specific property. GH-driven lipolysis preferentially targets visceral adipose tissue because visceral fat cells express higher densities of GH receptors and beta-adrenergic receptors than subcutaneous fat. The two Phase 3 trials fit this pattern: visceral fat dropped 14 to 18% while abdominal subcutaneous fat showed no significant change [6].
Because tesamorelin works through the pituitary, the hypothalamic feedback loop stays intact. Somatostatin is the natural brake on GH secretion. This self-regulating mechanism is why tesamorelin produces physiological pulsatile GH release rather than the flat supraphysiological elevation seen with exogenous HGH.
Tesamorelin Benefits
- Tesamorelin benefits center on FDA-validated visceral fat reduction and GH axis activation through the most potent available GHRH analog.
- Visceral fat fell 18% and 14% at 26 weeks in two double-blind Phase 3 trials of 816 patients. Waist circumference dropped 1 to 2 cm more than on placebo (EGRIFTA SV label, section 14). Pooled, the treatment effect on visceral fat was 15.4% [6].
- Liver fat cleared below 5% in 35% of patients at 12 months in Stanley et al.'s Lancet HIV RCT [2], with fibrosis progression significantly slowed across the trial.
- Cognitive function improved in a 152-person RCT (Baker et al. 2012)[3], showing better executive function and working memory in older adults and MCI patients after 20 weeks of GHRH treatment.
- IGF-1 typically rises 50 to 100% above baseline within four to six weeks, confirming GH axis activation and serving as a practical biomarker for peptide quality and injection technique.
- Sleep quality and recovery improvements within the first two weeks are among the most consistently reported early effects across community threads, preceding visible body composition changes by several weeks.
- Metabolic panel improvements, including triglyceride reduction and better lipid profiles, tracked in Phase 3 trial secondary endpoints and confirmed by off-label users monitoring bloodwork during 12 to 26 week cycles.
Tesamorelin: Science vs Community Consensus
FDA-approved GHRH analog with strong Phase 3 RCT data (n=816 randomized across two trials).
Read the evidence (key study, limitations)
VAT fell 18% and 14% at 26 weeks versus +2% and −2% on placebo (label section 14); the pooled treatment effect was −15.4% [6]. NAFLD benefit in HIV shown in Lancet HIV 2019 RCT (35% achieved liver fat <5% at 12 months). Cognitive benefit (executive function in MCI and healthy older adults) shown in 2012 RCT (n=152). 2024 INSTI-era study (n=61)[4] confirmed efficacy persists on modern ART regimens with no exacerbation of glycemic control. Active Phase 2 trial (TRIUMPH, NCT06554717) exploring exercise adjunct in HIV. Mechanism well-established: GHRH analog → pulsatile GH release → IGF-1 rise → visceral lipolysis. SC bioavailability <4% but potent at receptor level.
Falutz et al. 2010, J Clin Endocrinol Metab (PMID 20554713): pooled analysis of both Phase 3 trials (n=806), 26 weeks: VAT −24 vs. +2 cm² placebo, treatment effect −15.4%; −17.5% at 52 weeks with continued use. Falutz et al. 2010, JAIDS (PMID 20101189): the second trial alone (n=404), VAT −10.9% vs. −0.6% placebo at 26 weeks. Stanley et al. 2019 (PMID 31611038) Lancet HIV for NAFLD indication.
FDA approval limited to HIV-associated lipodystrophy; off-label use for general visceral fat reduction or cognition lacks large RCTs in non-HIV populations. SC bioavailability <4% means batch-to-batch potency variation in compounded product is clinically meaningful. Anti-tesamorelin antibodies in ~50% of patients (10% neutralizing in vitro at week 52), with comparable VAT and IGF-1 changes with or without them (label section 12.6). IGF-1 monitoring burden. No data in large non-HIV populations.
Regarded as the most targeted visceral fat peptide available.
Read the reports (what users report 5, common issues 5)
Community broadly follows the 2 mg/day Phase 3 trial dose (SC abdomen), above the 1.4 mg EGRIFTA SV label dose. Off-label use well-established among non-HIV users for belly fat reduction and GH optimization. Strong overlap between clinical expectations and community-reported outcomes. Primary criticisms: cost of compounded product, abdominal-only injection requirement, and IGF-1 testing burden.
- Visible reduction in abdominal visceral fat by weeks 8–12
- Waist circumference measurably decreases by month 3
- Improved sleep quality and body recomposition alongside fat loss
- Better metabolic markers (triglycerides, lipid profile) in some users
- Cognitive clarity and improved focus reported by users stacking for GH optimization
- High cost of compounded product ($150–$300/month) limits long-term use
- Abdominal-only injection requirement (per FDA label) limits site rotation options
- Joint pain and water retention in first 2–4 weeks
- Glucose increases monitored by users, especially those with metabolic syndrome
- Antibody formation over extended cycles may blunt response
Community dosing mirrors the 2 mg/day Phase 3 trial dose; the current EGRIFTA SV label dose is 1.4 mg/day. Reported outcomes for visceral fat reduction closely match the Phase 3 trial data. Off-label cognitive and GH optimization uses are an extension of the clinical mechanism, not a contradiction. Main divergence: community runs 3–6 month cycles with breaks whereas the FDA label supports ongoing continuous treatment.
Tesamorelin Dosage Guide
With a 5 mg vial and 2 mL bacteriostatic water, you get 2.5 mg/mL (2500 mcg/mL). At that concentration: 2000 mcg (the 2 mg Phase 3 trial dose most community protocols use) is 80 units on a U-100 insulin syringe. That's 0.8 mL, so you'll use close to half the syringe. Each 5 mg vial gives you 2.5 daily doses at 2 mg per day. The EGRIFTA SV label dose is lower: 1.4 mg (0.35 mL of its own reconstituted 2 mg vial) once daily.
With the 2 mg vial (EGRIFTA SV) and 0.5 mL of diluent, you get 4 mg/mL: 1.4 mg is 35 units (0.35 mL), and a 2 mg dose is the whole vial, 50 units (0.5 mL). Each 2 mg vial makes one dose.
Inject into abdominal subcutaneous fat only. The FDA label specifies this, and the clinical data was collected this way. Don't rotate to thigh or arm. Rotate within the abdomen, at least 2 cm from the umbilicus.
The non-obvious thing: your IGF-1 check at four to six weeks isn't optional. If IGF-1 hasn't risen, either the peptide is degraded, your injection technique is off, or you've drawn a bad batch from the compounder. Don't run a full 26-week cycle without confirming the molecule is actually working.
Pre-bed injection is the community preference for off-label use because it matches the natural nocturnal GH surge. FDA trials used morning dosing. Either works; consistency matters more than timing.
Cycling here is a community practice, not a label instruction. The FDA label supports ongoing treatment, and its immunogenicity data give no antibody reason to stop (EGRIFTA SV label, section 12.6). About 50% of patients formed anti-tesamorelin antibodies and 10% had neutralizing antibodies at week 52, with comparable VAT and IGF-1 changes either way. Community and clinic protocols add 4 to 8 week rest periods for cost, adherence, a pause in IGF-1 elevation and structured glucose checks. The trade-off is regain; VAT came back within six months of stopping in both trials (section 14).
Or use the universal Peptide Calculator for any peptide.
Tesamorelin Protocols by Goal
Expected: VAT −18% and −14% at 26 weeks in the two Phase 3 trials (n=816), with waist circumference down 1–2 cm more than placebo (label section 14). Liver fat reduction in NAFLD patients (35% achieved liver fat <5% at 12 months, Stanley 2019). IGF-1 rise at 4–6 weeks confirms GH axis activation.
Monitor: IGF-1 at baseline and 4–6 weeks, then every 6 months. Fasting glucose and HbA1c at baseline, then every 3–6 months. Waist circumference or DEXA/CT at baseline and 6 months. If IGF-1 >ULN: reduce or hold dose.
How to Inject Tesamorelin
- 1Gather your supplies
You'll need a 2 mg tesamorelin vial (lyophilized powder), 0.5 mL of diluent, a mixing syringe with an 18-gauge needle for reconstitution, and a U-100 insulin syringe (29 to 31 gauge, half-inch needle) for injection. EGRIFTA SV comes with its own diluent, and its label says to use only that one. Do not use bacteriostatic water with EGRIFTA SV. For a compounded vial, use the diluent your pharmacy names.
- 2Reconstitute the vial
Draw 0.5 mL of diluent into the mixing syringe. Inject slowly down the inside wall of the vial. Do not shake; roll the vial gently between your hands until the powder dissolves. This gives you 4 mg/mL. The solution should be clear and colorless; discard if cloudy or discolored.
- 3Draw your dose
Using a fresh U-100 insulin syringe, draw 35 units (0.35 mL) for the 1.4 mg EGRIFTA SV label dose. The 2 mg Phase 3 trial dose most community protocols use is 50 units (0.5 mL, the whole vial).
- 4Choose your injection site
Abdominal subcutaneous fat, at least 2 cm away from your navel. Avoid scar tissue and bruised areas. Rotate sites with each injection to prevent localized lipoatrophy.
- 5Clean the site with an alcohol swab and let it dry
Pinch a fold of skin, insert the needle at a 45 to 90 degree angle, inject slowly, hold for 5 seconds, then withdraw.
- 6Storage
Inject EGRIFTA SV right after mixing, then throw away what's left in the vial and the diluent bottle. Its label says not to refrigerate or freeze a mixed vial. For compounded vials, follow your pharmacy's storage directions.
- 7Timing
Pre-bed works well for off-label use (matches nocturnal GH pulse). Morning dosing was used in FDA trials. Pick one time and stay consistent.
- 8EGRIFTA WR is a different kit
Steps 1, 2, 3 and 6 above are for EGRIFTA SV. WR's 11.6 mg vial is mixed with 1.3 mL of the supplied bacteriostatic water, which gives 8 mg/mL. One 1.28 mg dose is 0.16 mL once daily, and the vial is discarded 7 days after mixing (WR label, section 2.2). WR and SV doses are not interchangeable (section 2.1).
Tesamorelin Stacking Protocols
Works With
Classic GHRH + GHRP dual-pathway stack. Tesamorelin provides the GHRH signal; ipamorelin provides the GHRP pulse: community protocols co-administer them for a larger combined GH release. Ipamorelin is the preferred GHRP for its clean profile. In swine it raised GH without raising cortisol or prolactin (PMID 9849822), and users report little hunger.
Inject both simultaneously or within 5 minutes. Tesamorelin 2000 mcg + ipamorelin 200–300 mcg, once daily SC abdomen.
Alternative GHRP. In swine, GHRP-2 released GH at a lower dose than ipamorelin (ED50 0.6 vs 2.3 nmol/kg) but reached a lower peak (56 vs 65 ng/mL; Raun 1998, PMID 9849822). In people it modestly raises cortisol and prolactin (Arvat 1997, PMID 9285939). Used when cortisol co-stimulation is acceptable.
Tesamorelin 2000 mcg + GHRP-2 100–200 mcg, once daily pre-bed SC abdomen.
Most potent GHRP available; produces the largest GH pulse per injection. Combined with tesamorelin for maximum GH axis activation in experienced users. Desensitization occurs faster than ipamorelin: typically cycled 4–8 weeks on, 4 weeks off.
Tesamorelin 2000 mcg + hexarelin 100–200 mcg, once daily SC abdomen. Short cycles only.
GLP-1 agonist + GHRH analog for dual-mechanism fat reduction. GLP-1 addresses subcutaneous and total body fat via appetite/insulin pathway; tesamorelin targets visceral fat specifically via GH pathway. Used in some telehealth clinic protocols for significant metabolic syndrome.
Avoid
Both tesamorelin and exogenous HGH elevate IGF-1. Combination risks supraphysiological IGF-1 levels, worsened insulin resistance, peripheral edema, and acromegaly-like effects with prolonged use. No clinical or community rationale for combining: choose one GH pathway strategy.
Do not combineBoth significantly raise GH and IGF-1 through complementary mechanisms (GHRH vs. ghrelin receptor). Combination produces excessive IGF-1 elevation and compounded insulin resistance risk. Glucose and metabolic effects are additive. Use one at a time.
Do not combineBoth are GHRH analogs: redundant mechanism. Both occupy GHRH receptors and produce pulsatile GH release. Combining two GHRH analogs does not increase efficacy and may cause receptor saturation and unnecessary IGF-1 burden.
Estimated Cost
Pricing updated 2026-04-09
Tesamorelin Side Effects
Glucose management is the most important safety concern with tesamorelin. GH-mediated insulin resistance is a class effect of all GHRH analogs, and the FDA label includes specific warnings about new-onset diabetes and glucose intolerance. Fasting glucose and HbA1c must be monitored at baseline, then every three to six months during treatment. A fasting glucose above 126 mg/dL or HbA1c above 6.5% means stopping or significantly adjusting the protocol. Pre-diabetic users and those with metabolic syndrome carry higher risk. The 2024 INSTI-era study (n=61)[4] confirmed that tesamorelin on modern ART regimens did not exacerbate glycemic control, but that data applies to the HIV population specifically.
Active malignancy is an absolute contraindication. Tesamorelin raises IGF-1, and IGF-1 promotes cell proliferation. The FDA label explicitly contraindicates use in patients with active or recurrent cancer. Newly diagnosed malignancy during treatment requires immediate discontinuation. This is not a theoretical concern; it's a black-box-level warning.
Anti-tesamorelin IgG antibodies showed up in 50% of trial patients at 26 weeks and 47% at 52 weeks (EGRIFTA SV label, section 12.6). Visceral fat and IGF-1 responses were similar with or without them. Neutralizing antibodies turned up in vitro in 10% by week 52, and changes in that group were comparable too.
Antibodies were far more common in people with hypersensitivity reactions, at 85% of that subset. Community protocols often add 4 to 8 week breaks; the label data give no antibody reason for them.
Injection site reactions are common in the first week: redness, pain, and induration at the abdominal injection site. The FDA label specifies abdominal subcutaneous injection only for this indication. Repeated injection into the same small area can cause localized lipoatrophy (skin dimpling) because tesamorelin triggers local lipolysis. Systematic site rotation across the abdomen prevents this. Avoid the area within 2 cm of the umbilicus and any scarred or bruised skin.
Joint pain and peripheral edema affect some users in the first two to four weeks as IGF-1 rises and fluid retention increases. Community reports describe this as self-resolving in most cases. If symptoms persist beyond four weeks, reducing the dose to 1 mg per day usually resolves them. NSAIDs help short-term for joint pain; leg elevation helps for lower extremity edema.
Pregnancy is contraindicated due to potential fetal harm per the FDA label. Breastfeeding lacks sufficient safety data.
Patients with disruption of the hypothalamic-pituitary axis from hypophysectomy, pituitary tumor, or pituitary surgery should not use tesamorelin, as the mechanism requires functional pituitary somatotrophs.
Known hypersensitivity to tesamorelin or mannitol (used as an excipient in the formulation) is a contraindication.
When to see a doctor: persistent edema beyond four weeks, fasting glucose above 126 mg/dL, joint pain unresponsive to dose reduction, any new or worsening mass or tumor, or signs of glucose intolerance.
Common Issues & Solutions
No measurable VAT reduction by week 8–10: verify injection technique (SC, not IM; rotate abdominal sites), confirm IGF-1 has risen from baseline at 4-week check. If IGF-1 not rising, suspect reconstitution error or inactive/degraded peptide; in the trials, IGF-1 rose similarly with or without anti-tesamorelin antibodies (label section 12.6).
Injection site lipoatrophy or skin dimpling: rotate sites systematically across the abdomen; avoid repeated injection into the same 1 cm area. Tesamorelin causes local lipolysis: a known effect that reverses when sites are properly rotated.
Fasting glucose rising: expected GH-mediated insulin resistance: must be monitored. At first sign of glucose rise >10 mg/dL from baseline, add quarterly HbA1c monitoring. In pre-diabetic users, consider dose reduction to 1 mg/day or discontinuation.
Response diminishing after initial benefit (months 3–6+): the label data do not support antibodies as the cause. ~50% of trial patients formed them and 10% had neutralizing antibodies by week 52, yet VAT and IGF-1 changes were comparable (label section 12.6). Recheck IGF-1, injection technique and product quality first.
Joint pain, stiffness, or peripheral edema: common in first 2–4 weeks as IGF-1 rises and fluid retention increases. Usually self-resolving. If persistent beyond 4 weeks or severe, reduce dose to 1 mg/day. Elevate legs for edema; NSAIDs for joint pain short-term.
Ask AI about this page
Ask AI for a second opinion on Tesamorelin dosing and side effects
Contraindications
- Active malignancy: newly diagnosed or recurrent cancer (tesamorelin may stimulate growth via IGF-1)
- Pregnancy: tesamorelin is contraindicated in pregnant women due to potential fetal harm
- Disruption of the hypothalamic-pituitary axis from hypophysectomy, pituitary tumor, or pituitary surgery
- Known hypersensitivity to tesamorelin or mannitol (excipient)
- Breastfeeding: insufficient data on excretion in human milk
Drug Interactions
- Cortisone and prednisone: tesamorelin may alter glucocorticoid metabolism via 11-beta-HSD1, potentially reducing cortisol conversion
- Medroxyprogesterone and norethindrone: tesamorelin may decrease levels by altering metabolism
- Phenytoin: tesamorelin may decrease phenytoin levels through metabolic alteration; monitor drug levels
- Theophylline: may decrease tesamorelin effectiveness by altering its metabolism
- Insulin and oral hypoglycemics: GH release from tesamorelin can reduce insulin sensitivity; monitor glucose and adjust diabetes medications
- Antiretroviral drugs (ritonavir, lopinavir/ritonavir): pharmacokinetic interactions studied in HIV population; consult Egrifta prescribing information for specific ART drug data
- Both significantly raise GH and IGF-1 through complementary mechanisms (GHRH vs. ghrelin receptor). Combination produces excessive IGF-1 elevation and compounded insulin resistance risk. Glucose and metabolic effects are additive. Use one at a time.
- Both are GHRH analogs: redundant mechanism. Both occupy GHRH receptors and produce pulsatile GH release. Combining two GHRH analogs does not increase efficacy and may cause receptor saturation and unnecessary IGF-1 burden.
Product Quality
Tesamorelin is an FDA-approved molecule (Egrifta SV, Egrifta WR) but most off-label community use is via compounded versions, not commercially manufactured Egrifta. Compounded peptides vary in purity, concentration accuracy, and sterility. SC bioavailability <4% means potency is highly sensitive to peptide integrity; degradation or incorrect concentration directly impacts dosing. FDA has taken enforcement action against compounding pharmacies for peptides in general (2024 503A bulk list enforcement activity). A COA from the compounding pharmacy is the main quality record for a compounded batch.
- Egrifta (tesamorelin) is on FDA's list of NDAs deemed to be biologics licenses on March 23, 2020, and FDA's notice to compounders says these transitioning biological products are not eligible for the 503A or 503B compounding exemptions. Unregulated research-chemical products have no oversight
- A useful certificate of analysis (COA) shows HPLC purity ≥98% and mass spec identity confirmation
- Reconstitute fresh; discard vials showing particulates, cloudiness, or color change
- EGRIFTA SV and WR vials store at room temperature (20-25°C) in the original box; inject SV right after mixing and discard WR 7 days after mixing. Compounded vials follow their pharmacy label
- If IGF-1 does not rise at 4-week check despite correct reconstitution and injection technique, suspect inactive peptide: contact provider
Recommended Monitoring
| Test | When | Target |
|---|---|---|
| IGF-1 (Insulin-like Growth Factor 1) | Baseline; 4–6 weeks into treatment; every 6 months thereafter | Age-adjusted normal range; generally <250 ng/mL for adults under 50; consult lab-specific age/sex reference ranges |
| Fasting Glucose | Baseline; 6–8 weeks; every 3 months | Fasting <100 mg/dL normal; 100–125 pre-diabetic; ≥126 diabetic |
| HbA1c | Baseline; every 3–6 months | <5.7% normal; 5.7–6.4% pre-diabetic; ≥6.5% diabetic |
| Waist Circumference | Baseline; monthly during active treatment | Reduction of ≥2 cm from baseline at 3 months expected for responders |
| Liver Enzymes (ALT, AST) | Baseline; at 3 and 6 months if using for NAFLD/liver fat indication | Not listed |
| Lipid Panel (Triglycerides, LDL, HDL) | Baseline; 6 months | Not listed |
Confirms GH axis activation. If IGF-1 not rising, peptide is inactive or injection technique is off. If above ULN, dose must be reduced or held.
GH-mediated insulin resistance is a known class effect of GHRH analogs. Early detection prevents progression to clinical hyperglycemia.
Longitudinal glycemic control marker. More sensitive than single fasting glucose for tracking trend over a treatment cycle.
Primary practical efficacy measure for VAT reduction. Correlates with CT/MRI VAT changes at population level.
Hepatic benefit shown in Stanley 2019 and INSTI-era 2024 data. Monitoring liver enzyme trends confirms or refutes hepatic response.
HIV-associated lipodystrophy includes dyslipidemia. Triglycerides often improve with VAT reduction. Confirms metabolic benefit beyond VAT in off-label users.
Tesamorelin Before and After
GH and IGF-1 levels begin to rise. Mild injection site reactions may occur. No visible body composition changes yet.
IGF-1 stabilizes at elevated levels. Improved sleep quality and recovery often reported. Early visceral fat mobilization begins.
Measurable reductions in visceral adipose tissue. Clinical trials showed significant VAT decrease by week 12. Waist circumference begins decreasing.
The two Phase III trials showed 18% and 14% visceral fat reductions at 26 weeks. Trunk fat and waist circumference significantly reduced. Lipid profiles may improve.
Sustained visceral fat reduction with continued use. NAFLD trial showed 35% of patients achieved liver fat below 5% at 12 months. Fibrosis progression significantly slowed.
What to Expect
Weeks 1 to 2: GH pulses ramp up and IGF-1 begins climbing toward a new steady state. Sleep quality often improves within the first week. No visible fat changes yet. Expect injection site redness and pain, mild water retention in hands and feet, and possibly some joint stiffness. These injection site reactions are most common in the first week and typically diminish.
Weeks 3 to 6: IGF-1 reaches its new raised plateau, generally 50 to 100% above baseline. This is your confirmation window; get IGF-1 checked at four to six weeks. Sleep improvement stays consistent. Some users notice their waistband fitting slightly looser. Energy and recovery start picking up. Injection site reactions have usually calmed down. Check fasting glucose, because peripheral edema should be resolving by now.
Weeks 6 to 12: Measurable visceral fat reduction begins showing up on imaging. Visceral fat loss at 26 weeks was 21 to 27 cm squared in the two Phase 3 trials (label section 14, Table 2). Waist tape readings start confirming what you can see in the mirror, typically 1 to 2 cm reduction. Most acute side effects have resolved by now. Glucose monitoring remains important.
Months 3 to 6: This is the peak response window. The two Phase 3 trials documented 18% and 14% visceral fat reductions at 26 weeks. Trunk fat and waist circumference drop significantly. Triglycerides and lipid profiles may improve. A 2024 INSTI-era cohort [4] showed 31% relative hepatic fat reduction. Body recomposition results are at their most visible. Some community reports describe a blunted response at this stage, though the label found similar visceral fat changes with or without antibodies.
Months 6 to 12: Continued use maintains the visceral fat reduction, but the NAFLD trial is where the long game pays off: 35% of patients achieved liver fat below 5% at 12 months (Stanley et al. 2019)[2], and fibrosis progression slowed significantly. Most community protocols include a break at six months, cycling off for four to eight weeks before re-challenging. Expect some regain; in the trials, visceral fat came back within six months of stopping. Glucose management is the primary ongoing monitoring concern; check HbA1c at minimum.
Detailed Timeline: Science vs Community
GH pulses increase; IGF-1 begins rising toward new elevated steady state. Injection site reactions (redness, pain, induration) common in first week.
Sleep quality often improves within the first week. No visible fat changes. Some note mild water retention in hands/feet. Joint stiffness possible.
IGF-1 reaches new elevated plateau (~50–100% above baseline). Visceral fat mobilization begins at cellular level via GH-mediated lipolysis. Check IGF-1 at 4–6 weeks.
Sleep quality consistently improved. Some notice waistband fitting slightly looser. Energy and recovery improving. Injection site reactions usually diminishing.
VAT reduction builds on CT/MRI imaging; at 26 weeks the two Phase 3 trials measured −21 to −27 cm² (label section 14, Table 2). Waist circumference begins measurably decreasing.
Visible abdominal changes: "visceral fullness" reducing. Waist tape showing 1–2 cm reduction. Users report improved definition despite no other protocol changes.
VAT −18% and −14% at 26 weeks in the two Phase 3 trials (label section 14). Trunk fat and waist circumference significantly reduced. Triglycerides and lipid profiles may improve. 31% relative hepatic fat reduction in 2024 INSTI cohort (PMID 38905488).
Most dramatic body recomposition results. Users report 1–3 cm waist circumference reduction. Abdominal definition noticeably improved. A minority report a blunted response at this stage and blame antibodies; the label found similar VAT changes with or without them.
NAFLD trial showed 35% achieved liver fat <5% at 12 months. Fibrosis progression significantly slowed. Continued VAT suppression with sustained use. VAT tends to return toward baseline within 6–12 months of stopping.
Users continuing long-term note sustained results. Some report response blunting. Most community protocols include a break at 6 months, then re-challenge.
Pharmacokinetics
Source: EGRIFTA SV label (DailyMed SPL v9, July 2026) section 12.3: mean t1/2 8 min after a single 1.4 mg SC dose in healthy subjects; EGRIFTA WR label (SPL v2): 11 min after a single 1.28 mg SC dose. Drawn at the ~9.5 min midpoint
Pharmacokinetics: Active Dose Over Time
t½ = 8-11 min (single SC dose, EGRIFTA SV and WR labels)Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only, not medical advice.
Molecular Profile
Is Tesamorelin Legal?
Tesamorelin is FDA-approved (BLA 022505, an NDA until FDA deemed it a BLA on March 23, 2020) under the brand name Egrifta for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. The original approval came in November 2010; the current EGRIFTA SV and EGRIFTA WR labels are dated July 29, 2026. This is one of a very small number of peptides with full FDA approval, Phase 3 RCT data, and an active commercial product.
Commercially manufactured Egrifta SV and Egrifta WR are available through specialty pharmacies with a prescription. Brand pricing runs approximately $3,085 per month as a typical US cash price without insurance, or roughly $41,000 per year list price. Patient assistance programs exist for qualifying patients.
Off-label use for general visceral fat reduction, body recomposition, or cognitive support requires a prescription from a licensed provider. Most off-label users get tesamorelin as a compounded formulation, typically at $150 to $300 per month.
The FDA took enforcement actions against compounding pharmacies for peptides broadly in 2024. Egrifta is on FDA's list of applications deemed to be biologics licenses on March 23, 2020. FDA's notice to compounders says these transitioning biological products are not eligible for the 503A and 503B compounding exemptions. Tesamorelin also appears in none of FDA's 503A or 503B nomination categories (May 14, 2026; March 21, 2025).
WADA prohibits all growth hormone releasing factors including tesamorelin for competitive athletes.
This content is for informational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. Consult a qualified healthcare provider before using any peptide.
Who Should Consider Tesamorelin
- HIV-positive patients with lipodystrophy and excess visceral adipose tissue
- Individuals seeking visceral belly fat reduction
- Patients with non-alcoholic fatty liver disease (NAFLD) under clinical investigation
- Adults pursuing GH optimization through pulsatile release
- Patients interested in cognitive support via GH pathway activation
Related Peptides
What Changed for Tesamorelin
- Safety
Corrected Oct 15, 2026: tesamorelin side effects no longer say neutralizing antibodies blunt fat loss; responses were comparable, per the EGRIFTA SV label.
Before: A subset of 10 to 15% develop neutralizing antibodies that blunt the VAT response; cycling 26 weeks on, 4 to 8 weeks off, restores it After: Antibodies in 50% at 26 weeks and 47% at 52 weeks; neutralizing in 10% at week 52, with comparable VAT and IGF-1 changes (label section 12.6)
What this does not mean: Antibodies still formed in about half of trial patients, and in 85% of those with hypersensitivity reactions. Community protocols may still take breaks; the label gives no antibody reason for them.
Source: EGRIFTA SV (tesamorelin) prescribing information, section 12.6 Immunogenicity (openFDA label record, SPL version 9, effective Jul 29, 2026) (opens in a new tab) · Saved copy
- Dosing
Corrected Oct 11, 2026: tesamorelin tiers are the EGRIFTA SV label dose, 1.4 mg once daily, not 2 mg; EGRIFTA WR is 1.28 mg, per the FDA labels.
Before: Every tier 2 mg (2,000 mcg) daily, cited to the FDA label After: Every tier 1.4 mg (1,400 mcg) once daily, the EGRIFTA SV label dose; EGRIFTA WR, not substitutable, is 1.28 mg once daily
Source: EGRIFTA SV (tesamorelin) prescribing information (openFDA label record, SPL version 9, effective Jul 29, 2026) (opens in a new tab) · Saved copy
Dates to watch
- Trial primary completion, estimated
A Phase 2 trial of tesamorelin with exercise for physical function in HIV has an estimated primary completion date, per ClinicalTrials.gov.
What this does not mean: Primary completion is when the last participant gives data for the main outcome, not when results come out. Estimated dates often move.
Peptide Schedule Research TeamReviewed Apr 7, 202622 Citations
References
- [1]Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension (Falutz et al., J Acquir Immune Defic Syndr 2010) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [2]Effects of tesamorelin on non-alcoholic fatty liver disease in HIV (Stanley et al., Lancet HIV 2019) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [3]Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults (Baker et al., Arch Neurol 2012) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [4]Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors (Russo et al., AIDS 2024) (opens in a new tab)(n=61,)PubMed (opens in a new tab)PubMed
- [5]FDA BLA 022505 (NDA until 2020)
- [6]Effects of tesamorelin (TH9507) in HIV-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data (Falutz et al., J Clin Endocrinol Metab 2010) (opens in a new tab)(n=806)PubMed (opens in a new tab)PubMed
Additional References
- Tesamorelin: a review of its use in HIV-associated lipodystrophy (Dhillon, Drugs 2011) (opens in a new tab)PubMed 21668043PubMed
- Spotlight on tesamorelin in HIV-associated lipodystrophy (BioDrugs 2011) (opens in a new tab)PubMed 22050344PubMed
- Tesamorelin (Nat Rev Drug Discov 2011) (opens in a new tab)PubMed 21283099PubMed
- Egrifta (tesamorelin) FDA Prescribing Information (opens in a new tab)FDA Label
- EGRIFTA SV (tesamorelin) prescribing information, DailyMed, July 2026 (sections 12.6 Immunogenicity and 14 Clinical Studies) (opens in a new tab)FDA Label
- Phase 2 trial (NCT06554717) (opens in a new tab)Clinical Trial
- Body composition, hepatic fat, metabolic, and safety outcomes of tesamorelin in HIV-associated lipodystrophy: Meta-analysis (Obes Res Clin Pract 2026) (opens in a new tab)PubMed 41545261PubMed
- Delineating tesamorelin response pathways in HIV-associated NAFLD using targeted proteomic and transcriptomic approach (Sci Rep 2021) (opens in a new tab)PubMed 34006921PubMed
- Growth Hormone Releasing Hormone Reduces Circulating Markers of Immune Activation in Parallel with Effects on Hepatic Immune Pathways (Clin Infect Dis 2021) (opens in a new tab)PubMed 33852720PubMed
- Relationship of IGF-1 and IGF-Binding Proteins to Disease Severity and Glycemia in Nonalcoholic Fatty Liver Disease (J Clin Endocrinol Metab 2021) (opens in a new tab)PubMed 33125080PubMed
- FDA: Notice to compounders, changes that affect compounding as of March 23, 2020 (content current as of March 5, 2020) (opens in a new tab)Review
- FDA: List of approved NDAs for biological products that were deemed to be BLAs on March 23, 2020 (opens in a new tab)Review
- FDA: Bulk drug substances nominated for use in compounding under section 503A, categories (updated May 14, 2026) (opens in a new tab)Review
- FDA: Bulk drug substances nominated for use in compounding under section 503B, categories (updated March 21, 2025) (opens in a new tab)Review
- Ipamorelin, the first selective growth hormone secretagogue (Raun et al., Eur J Endocrinol 1998) (opens in a new tab)PubMed 9849822PubMed
- Effects of GHRP-2 and hexarelin, two synthetic GH-releasing peptides, on GH, prolactin, ACTH and cortisol levels in man (Arvat et al., Peptides 1997) (opens in a new tab)PubMed 9285939PubMed
Related Resources
Related Tools
Storage & Stability
Frequently Asked Questions
How popular is Tesamorelin?
Popular. A popularity tier (hot, popular, emerging or niche), based on search volume and community activity.
110 papers on PubMed, the US library of medical research. Search them on PubMed (opens in a new tab).
Moderate search interest. A band for how often people search Google for the name each month.
These come from this site's peptide records. They are not live counts.